| Crystal structure of a soluble cleaved HIV-1 envelope trimer | Science | 2013 | 687 |
| Rational HIV immunogen design to target specific germline B cell receptors | Science | 2013 | 519 |
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Journal of Virology | 2009 | 458 |
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Nature Medicine | 2009 | 449 |
| Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers | PLoS Pathogens | 2009 | 409 |
| HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Science | 2015 | 394 |
| Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Proceedings of the National Academy of Sciences of the United States of America | 2012 | 376 |
| Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design | Annual Review of Immunology | 2016 | 366 |
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Nature Medicine | 2009 | 357 |
| Structural basis of a shared antibody response to SARS-CoV-2 | Science | 2020 | 338 |
| Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses | Science | 2012 | 334 |
| Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer | Science | 2016 | 319 |
| Antibody responses to envelope glycoproteins in HIV-1 infection | Nature Immunology | 2015 | 304 |
| Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G | Cell | 2016 | 301 |
| Hepatitis C virus E2 envelope glycoprotein core structure | Science | 2013 | 300 |
| Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers | Immunity | 2014 | 286 |
| Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens | Proceedings of the National Academy of Sciences of the United States of America | 2010 | 275 |
| Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L | Journal of Virology | 2010 | 273 |
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen | Science | 2015 | 264 |
| Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus | Proceedings of the National Academy of Sciences of the United States of America | 2012 | 256 |
| Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120 | Science | 2009 | 249 |
| Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex | Proceedings of the National Academy of Sciences of the United States of America | 2014 | 239 |
| Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors | Cell | 2015 | 219 |
| Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody | Science | 2016 | 218 |
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Proceedings of the National Academy of Sciences of the United States of America | 2011 | 206 |
